Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 293 participants.
Also called NCT02517320
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 293 participants
- Sponsor
- Registry
-
NCT02517320
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02517320. Randomized; quadruple masking; primary purpose treatment. Start 2015-07 (registry gives no type); primary completion 2016-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy
- Condition
- Diabetic Nephropathy
- Intervention (Drug)
- MT-3995 Low
- Intervention (Drug)
- MT-3995 Middle
- Intervention (Drug)
- MT-3995 High
- Intervention (Drug)
- Placebo
- Lead sponsor
- Tanabe Pharma Corporation
Record details
- Record id
cardio:ct-nct02517320- Content hash
a5908f638195c6d2eb2b094c596532f23ee8fbc50620f93766630d585f7407a3